Using low doses of interleukin-2 to improve immune response in Crohn's disease

Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn’s Disease

NIH-funded research Boston Children's Hospital · NIH-10892193

This study is looking at whether a low dose of a medicine called interleukin-2 can help boost the immune system's regulatory cells in people with Crohn's disease, especially for those who haven't had good results with other treatments.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBoston Children's Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10892193 on NIH RePORTER

What this research studies

This research investigates the use of low-dose interleukin-2 (IL-2) to enhance the function of regulatory T cells (Tregs) in patients with Crohn's disease, a type of inflammatory bowel disease. By selectively expanding Tregs, which help regulate the immune system, the study aims to improve treatment outcomes for patients who do not respond well to existing therapies. The approach is based on previous findings that low-dose IL-2 is safe and effective in other conditions, and it will involve clinical trials to assess its impact on Crohn's disease symptoms and progression.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Crohn's disease who have not achieved satisfactory results from current treatments.

Not a fit: Patients with other forms of inflammatory bowel disease, such as ulcerative colitis, or those who are not diagnosed with Crohn's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could provide a new therapeutic option for patients with Crohn's disease, potentially improving their quality of life and disease management.

How similar studies have performed: Previous studies have shown that low-dose IL-2 can effectively expand Tregs and has been safe in other clinical settings, suggesting a promising avenue for treatment in Crohn's disease.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.